Doctor-Prescribed Peptides in Australia: What the New AHPRA Guidance Says

Updated September 2026

As interest in peptide medicines continues to grow in Australia, the Australian Health Practitioner Regulation Agency (Ahpra) and the National Boards have published guidance for registered health practitioners on prescribing off-label, unapproved or compounded medicines. The guidance is accompanied by case studies designed to help practitioners understand their professional responsibilities and apply good-practice principles when making prescribing decisions. (Ahpra, 2026)

The guidance is particularly relevant to the discussion around doctor-prescribed peptides, as one of Ahpra’s case studies specifically examines the prescribing of unapproved peptides. (Ahpra, 2026)

At GL Vitality Drips, we believe it is important for clients to have access to current information about the Australian regulatory and professional environment surrounding medicines and peptides.

This article summarises the key points from the current Ahpra guidance and its unapproved-peptide case study. It is intended as general educational information and does not replace advice from an appropriately qualified health practitioner or regulator.

What is the new Ahpra guidance about?

Ahpra and the relevant National Boards have published guidance addressing the prescribing of off-label, unapproved and compounded medicines. The accompanying case studies are intended to help practitioners reflect on prescribing decisions, understand their professional responsibilities and apply good-practice principles so patients can make informed decisions and receive safe and effective care. (Ahpra, 2026)

The guidance covers circumstances where a practitioner considers prescribing a medicine:

• off-label;
• unapproved; or
• compounded.

The case studies illustrate how considerations such as clinical need, available evidence, informed consent, documentation, monitoring and review can apply in practice. (Ahpra, 2026)

What does this mean for doctor-prescribed peptides?

The Ahpra guidance does not state that all peptides cannot be prescribed.

Instead, its unapproved-peptide case study focuses on the professional responsibilities involved when a practitioner considers prescribing an unapproved medicine. (Ahpra, 2026)

The case study makes clear that a patient’s request for a particular unapproved medicine does not, by itself, establish an appropriate reason for prescribing it. Practitioners are expected to consider whether there is an established reason for using the medicine for the particular patient and whether the decision is supported by appropriate evidence. (Ahpra, 2026)

This means that the phrase “doctor-prescribed peptides” should not be interpreted as meaning that a patient can simply request a particular peptide and receive a prescription.

The prescribing decision remains a clinical decision made by the appropriately authorised practitioner, taking into account the individual patient’s circumstances and applicable professional and regulatory requirements. (Ahpra, 2026)

Ahpra’s specific case study on unapproved peptides

One of the new Ahpra case studies is specifically titled “Informed consent goes beyond patient request: lessons learned from unsafe prescribing of unapproved medicines.” (Ahpra, 2026)

In the case study, a doctor prescribed a range of unapproved peptides promoted for purposes including “anti-ageing” and “faster muscle repair” after several patients requested them. (Ahpra, 2026)

The doctor prescribed the peptides without adequately assessing the evidence for their safety, quality or effectiveness for the individual patients. The doctor also did not clearly explain that the peptides were unapproved medicines or discuss the associated risks and unknowns. (Ahpra, 2026)

In some cases, the peptides were prescribed following brief consultations involving limited clinical assessment and minimal documentation in the medical record. Two patients experienced adverse reactions and stopped taking the peptides. (Ahpra, 2026)

Ahpra identifies four key lessons from this case study:

• There should be an established reason for using the medicine for the particular patient.
• The decision should be supported by appropriate evidence.
• The practitioner should document their decision-making and consent discussions.
• Patients should understand that the medicine is unapproved, including possible risks, unknowns and available alternatives, so they can make an informed decision.

1. There should be an established reason for prescribing

Ahpra’s case study states that before prescribing an unapproved medicine, practitioners should ensure there is an established reason for using that treatment for the particular patient. (Ahpra, 2026)

This is important because a patient’s interest in a particular peptide does not, on its own, establish clinical need.

The practitioner needs to consider the individual patient’s circumstances and whether there is an appropriate reason to consider the medicine. (Ahpra, 2026)

2. The decision should be supported by appropriate evidence

Ahpra’s case study states that the decision to prescribe an unapproved medicine should be supported by appropriate evidence. (Ahpra, 2026)

The peptide case study specifically highlights the need to adequately assess evidence relating to safety, quality and effectiveness for the individual patient before prescribing an unapproved peptide. (Ahpra, 2026)

This is particularly relevant when discussing peptides because the term “peptide” describes a broad group of molecules rather than a single medicine or regulatory category.

The TGA notes that some peptide-based medicines are approved and included in the ARTG, while unapproved peptide products are those that have not been included in the ARTG. (TGA, 2026c)

3. Patients should understand when a medicine is unapproved

Ahpra’s case study specifically states that patients should understand that an unapproved medicine is unapproved, including the possible risks, unknowns and available alternatives. (Ahpra, 2026)

This allows the patient to make an informed decision about their treatment. (Ahpra, 2026)

The TGA defines an unapproved therapeutic good as a therapeutic good that is not included in the Australian Register of Therapeutic Goods (ARTG). The TGA states that unapproved therapeutic goods have not been assessed by the TGA for safety, quality or effectiveness in the same way as ARTG-included products. (TGA, 2026a)

Importantly, an unapproved medicine may be able to be accessed under certain Australian regulatory pathways where the relevant requirements are met. The TGA identifies pathways including the Special Access Scheme, Authorised Prescriber Scheme and clinical-trial pathways. (TGA, 2026a)

Therefore, “unapproved” does not automatically mean “cannot ever be accessed”, but access is subject to the applicable regulatory framework and requirements. (TGA, 2026a)

4. Clinical reasoning and consent should be documented

Ahpra’s peptide case study states that practitioners should document their decision-making and consent discussions when prescribing an unapproved medicine. (Ahpra, 2026)

The purpose is to ensure there is an appropriate clinical record of the prescribing decision and the information discussed with the patient. (Ahpra, 2026)

The broader Ahpra case studies similarly emphasise documentation of clinical reasoning and patient consent when prescribing off-label or compounded medicines. (Ahpra, 2026)

What does “off-label” mean?

Off-label prescribing is different from prescribing an unapproved medicine.

An off-label medicine is an approved medicine being used outside the conditions for which it has been approved.

The Ahpra case study provides an example involving domperidone being considered for an off-label use. In that example, the practitioner reviewed the available evidence and relevant policies, assessed potential risks and benefits, discussed the off-label use and alternatives with the patient, obtained informed consent, documented the decision and established monitoring and follow-up arrangements. (Ahpra, 2026)

The key distinction is therefore:

• Off-label: an approved medicine is being used outside its approved conditions.
• Unapproved: the therapeutic good is not included in the ARTG for the relevant purpose. (TGA, 2026a)

What are compounded medicines?

The Ahpra guidance also addresses compounded medicines. Its case study explains that practitioners should have a clear clinical reason why an approved medicine cannot be used before prescribing a compounded medicine. (Ahpra, 2026)

The TGA describes compounded medicines as medicines prepared for an individual patient when an approved, ready-made medicine is not suitable. Examples can include situations where a patient requires a different dose, formulation or ingredient profile. (TGA, 2026b)

The TGA classifies compounded medicines as unapproved therapeutic goods because they are not individually evaluated by the TGA for safety, quality or efficacy before supply. (TGA, 2026b)

The TGA states that compounded medicines may be supplied under specific exemptions where the relevant conditions are met, including circumstances involving an individual patient and a valid prescription or request. (TGA, 2026b; TGA, 2026c)

What does informed consent mean?

The Ahpra peptide case study highlights that informed consent goes beyond a patient’s request for a particular medicine. (Ahpra, 2026)

In the case study, the doctor incorrectly assumed that a patient’s request demonstrated sufficient knowledge to provide informed consent. Ahpra identifies this as a key lesson from the case. (Ahpra, 2026)

For an unapproved medicine, Ahpra states that patients should understand that the medicine is unapproved and should be informed about possible risks, unknowns and available alternatives. (Ahpra, 2026)

This information supports patients in making an informed decision about their treatment. (Ahpra, 2026)

What about monitoring and review?

The Ahpra guidance also highlights the importance of ongoing monitoring and review.

In its off-label prescribing case study, the practitioner established a clear plan for monitoring and follow-up and intended to review the patient’s progress regularly, including discontinuing the medicine if it was not effective or when it was no longer required. (Ahpra, 2026)

In the compounded-medicine case study, Ahpra similarly identifies ongoing monitoring and regular review as key responsibilities for assessing effectiveness and identifying potential side effects. (Ahpra, 2026)

What does the TGA say about unapproved peptide products?

The TGA has separately issued guidance concerning unapproved peptide products.

The TGA states that peptide products are regulated as therapeutic goods in Australia and that some peptide-based medicines, such as insulin products, are approved and included in the ARTG. (TGA, 2026c)

The TGA defines unapproved peptide products as products that have not been included in the ARTG. (TGA, 2026c)

The TGA has expressed concern about the increasing importation, supply, compounding and advertising of unapproved peptide products and has warned about products being promoted online with claims relating to areas such as weight loss, muscle growth, anti-ageing and cognitive or athletic performance. (TGA, 2026c)

This TGA guidance is separate from the Ahpra professional guidance, but the two are relevant to different aspects of the same broader environment: Ahpra addresses professional responsibilities of registered practitioners, while the TGA regulates therapeutic goods and their supply and advertising under the therapeutic goods framework. (Ahpra, 2026; TGA, 2026c)

Doctor-prescribed does not automatically mean TGA-approved

One of the most important distinctions for consumers is that a prescription and TGA approval are not the same thing.

A medicine may be prescribed in circumstances involving an approved medicine, an off-label use, an unapproved therapeutic good or a compounded medicine, depending on the circumstances and applicable requirements. (Ahpra, 2026; TGA, 2026a)

The TGA states that certain unapproved therapeutic goods may be accessed through defined pathways, including the Special Access Scheme and Authorised Prescriber Scheme, subject to the relevant requirements. (TGA, 2026a)

Accordingly, “doctor-prescribed peptide” should not automatically be understood to mean “TGA-approved peptide.”

What does the new guidance mean for clients researching peptides?

For people researching doctor-prescribed peptides in Australia, the new Ahpra guidance provides useful context about what responsible prescribing should involve.

The guidance emphasises that prescribing an off-label, unapproved or compounded medicine involves more than responding to a patient’s request. Practitioners should consider the clinical need, available evidence, informed consent, documentation and appropriate monitoring and review. (Ahpra, 2026)

For unapproved peptides specifically, Ahpra’s case study highlights the importance of establishing a reason for prescribing the medicine for the particular patient, assessing appropriate evidence, explaining the unapproved status and documenting the prescribing and consent process. (Ahpra, 2026)

Key points from the new Ahpra guidance

What does this mean for peptide prescribing in Australia?

The September 2026 Ahpra guidance provides an updated framework for understanding the professional responsibilities associated with prescribing off-label, unapproved and compounded medicines. (Ahpra, 2026)

Its specific unapproved-peptide case study highlights several principles: clinical justification, appropriate evidence, informed consent, documentation and understanding of risks and unknowns. (Ahpra, 2026)

The TGA’s separate guidance also confirms that unapproved peptide products are subject to Australia’s therapeutic goods regulatory framework and that access, supply and advertising are subject to specific requirements. (TGA, 2026c)

Together, these resources provide an important current reference point for anyone researching peptides in Australia.

Staying up to date

The regulatory environment surrounding medicines and peptides continues to develop.

At GL Vitality Drips, we monitor relevant Australian regulatory and professional guidance and update our educational information as new guidance and announcements are released.

Our role is to support clients through a practitioner-guided wellness journey, while prescribing decisions remain with the appropriately authorised healthcare practitioner.

The information provided on this page is intended to summarise publicly available regulatory and professional guidance and is not a substitute for individual medical, legal or regulatory advice.

Frequently Asked Questions

Can a doctor prescribe peptides in Australia?

Whether a particular peptide can be prescribed depends on its regulatory status, the individual clinical circumstances and the applicable professional and regulatory requirements. Ahpra’s current guidance addresses professional responsibilities when practitioners prescribe off-label, unapproved or compounded medicines. (Ahpra, 2026)

Does a doctor’s prescription mean a peptide is TGA-approved?

No. A prescribing decision and TGA approval are separate matters. Some unapproved therapeutic goods may be accessed through specific regulatory pathways where the relevant requirements are met. (TGA, 2026a)

What does Ahpra say about unapproved peptides?

Ahpra’s specific unapproved-peptide case study states that practitioners should establish a reason for using the medicine for the particular patient, ensure the decision is supported by appropriate evidence, document decision-making and consent, and ensure patients understand the medicine is unapproved, including possible risks, unknowns and alternatives. (Ahpra, 2026)

Does Ahpra prohibit peptide prescribing?

The unapproved-peptide case study does not state that all peptide prescribing is prohibited. Instead, it sets out lessons concerning the professional responsibilities involved in prescribing unapproved medicines. (Ahpra, 2026)

Are compounded medicines TGA-approved?

Compounded medicines are generally unapproved therapeutic goods and are not individually evaluated by the TGA for safety, quality and efficacy before supply. Specific exemptions can allow certain compounded medicines to be supplied where the applicable conditions are met. (TGA, 2026b; TGA, 2026c)

Official sources

• Australian Health Practitioner Regulation Agency (Ahpra) — Prescribing off-label, unapproved or compounded medicines — Case studies: Meeting your professional obligations when prescribing off-label, unapproved or compounded medicines. (Ahpra, 2026)
• Therapeutic Goods Administration (TGA) — Unapproved therapeutic goods. (TGA, 2026a)
• Therapeutic Goods Administration (TGA) — Compounded medicines. Updated 14 May 2026. (TGA, 2026b)
• Therapeutic Goods Administration (TGA) — Manufacturing, supplying and advertising compounded medicines lawfully. Updated 8 September 2026. (TGA, 2026)
• Therapeutic Goods Administration (TGA) — Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Published 13 April 2026. (TGA, 2026c)

Information current to September 2026. Regulatory and professional requirements may change.

Related reading

• What Is a Schedule 4 Medicine in Australia?
• What Is the ARTG? Understanding Australia’s Register of Therapeutic Goods
• What Is a Compounded Medicine? Understanding Pharmaceutical Compounding in Australia
• Approved vs Unapproved Therapeutic Goods: What Is the Difference?
• Are Peptides Legal in Australia? Understanding Regulation and Access